CagriSema bone density data at ObesityWeek point to a calcitonin receptor role
Novo Nordisk showed rat, volunteer and post hoc REDEFINE 1 data suggesting amylin and calcitonin receptor drugs may limit bone loss during weight loss. The company calls the work hypothesis generating, and fractures were not studied.
PLAINSBORO, NJ
- What's newNovo Nordisk presented rat, volunteer and post hoc REDEFINE 1 data at ObesityWeek 2026 suggesting that activating amylin and calcitonin receptors may limit bone loss during weight loss.
- Why it mattersLarge weight loss can thin bone and raise fracture risk, a concern for older women, and CagriSema is under FDA review for weight management.
- What's nextNovo says longer clinical studies are needed to test bone outcomes, and an FDA decision on CagriSema is expected in the fourth quarter of 2026.